Clinical Trials Logo

Pituitary Diseases clinical trials

View clinical trials related to Pituitary Diseases.

Filter by:

NCT ID: NCT01444209 Terminated - Clinical trials for Pituitary Macroadenoma

Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas

Start date: September 30, 2011
Phase: Phase 2
Study type: Interventional

This study is a single arm Phase II pilot trial. Patients enrolled on the trial will undergo implantation of high activity iodine-125 seeds into their pituitary adenoma. The tumor response to treatment will be monitored as well as change in visual fields, associated adverse effects, progression free survival and patient reported outcomes.

NCT ID: NCT01088763 Terminated - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This phase I/II clinical trial is studying the side effects and best dose of gamma-secretase inhibitor RO4929097 and to see how well it works in treating young patients with relapsed or refractory solid tumors, CNS tumors, lymphoma, or T-cell leukemia. Gamma-secretase inhibitor RO4929097 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00798057 Terminated - Pituitary Adenoma Clinical Trials

Proton Radiation Therapy for Pituitary Adenoma

PI01
Start date: October 2007
Phase: N/A
Study type: Observational

The purpose of this study is to collect information from medical records to see what effects proton beam radiation has on pituitary tumors and analyze possible side effects.

NCT ID: NCT00646308 Terminated - Clinical trials for Growth Hormone Deficiency

Assessment of Cardiovascular Risk Markers in Growth Hormone Deficient Patients With Nonsecreting Pituitary Adenomas

Start date: March 2008
Phase: N/A
Study type: Observational

The purpose of this study is to determine if patients with a history of nonsecreting pituitary adenomas with untreated GH deficient patients have profiles consistent with increased cardiovascular risk compared to patients without GH deficiency who have undergone similar surgery.

NCT ID: NCT00616642 Terminated - Clinical trials for Brain and Central Nervous System Tumors

Rosiglitazone in Treating Patients With Pituitary Tumors

Start date: October 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Rosiglitazone may help pituitary adenoma cells become more like normal cells, and grow and spread more slowly. PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed or residual or recurrent pituitary adenoma.